Hosted on MSN
The future of obesity management—quintuple and other super polyagonists for weight loss and maintenance?
Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors (single agonists such as semaglutide) and also dual glucose-dependent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback